Osteopontin is involved in estrogen-mediated protection against diethylnitrosamine-induced liver injury in mice

Food and Chemical Toxicology

Volumn 50, Issue 8, 2012, Pages 2878-2885

  He, Chunyan ^a,b   Fan, Xiaoyu ^b,c   Chen, Rui ^b,c   Liang, Beibei ^a,b   Cao, Lei ^a,b   Guo, Yajun ^a,b,c   Zhao, Jian ^b,c  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Diethylnitrosamine; Estrogen; Liver injury; Osteopontin; Reactive oxygen species

Indexed keywords

CYTOCHROME P450 2A5; DIETHYLNITROSAMINE; ESTRADIOL; OSTEOPONTIN; RECOMBINANT OSTEOPONTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; LIVER PROTECTION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; SEX DIFFERENCE; TOXIC HEPATITIS;

ANIMALS; DIETHYLNITROSAMINE; ESTROGENS; FEMALE; LIVER; MALE; MICE; MICE, INBRED C57BL; OSTEOPONTIN; REAL-TIME POLYMERASE CHAIN REACTION;

ANIMALIA; MUS;

EID: 84862681294     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.05.012     Document Type: Article

References (59)

1. Adams D.H., Ju C., Ramaiah S.K., Uetrecht J., Jaeschke H. Mechanisms of immune-mediated liver injury. Toxicol. Sci. 2010, 115:307-321.
2. Akintonwa D.A. The derivation of nitrosamines from some therapeutic amines in the human environment. Ecotoxicol. Environ. Saf. 1985, 9:64-70.
3. Asamoto M., Shichino Y., Tsuda H., Ito N. Inhibition of rat hepatic glutathione S-transferase placental form positive foci development by concomitant administration of antioxidants to carcinogen-treated rats. Cancer Lett. 1990, 55:25-29.
4. Atul Sahai P.M., Melin-Aldana Hector., Green Richard.M., Whitington Peter.F. Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 287:264-273.
5. Baliga S.S., Merrill G.F., Shinohara M.L., Denhardt D.T. Osteopontin expression during early cerebral ischemia-reperfusion in rats: enhanced expression in the right cortex is suppressed by acetaminophen. PLoS One 2011, 6:e14568.
6. Barna B.P., Thomassen M.J., Zhou P., Pettay J., Singh-Burgess S., Deodhar S.D. Activation of alveolar macrophage TNF and MCP-1 expression in vivo by a synthetic peptide of C-reactive protein. J. Leukocyte Biol. 1996, 59:397-402.
7. Bartsch H., Hietanen E., Malaveille C. Carcinogenic nitrosamines: free radical aspects of their action. Free Radical Biol. Med. 1989, 7:637-644.
8. Bartsch H., Spiegelhalder B. Environmental exposure to N-nitroso compounds (NNOC) and precursors: an overview. Eur. J. Cancer Prev. 1996, 5(Suppl 1):11-17.
9. Boffetta P., Hecht S., Gray N., Gupta P., Straif K. Smokeless tobacco and cancer. Lancet Oncol. 2008, 9:667-675.
10. Camus A.M., Geneste O., Honkakoski P., Bereziat J.C., Henderson C.J., Wolf C.R., Bartsch H., Lang M.A. High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol. Carcinog. 1993, 7:268-275.
11. Cantor H., Shinohara M.L. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat. Rev. Immunol. 2009, 9:137-141.
12. Chandrasekaran V.R., Periasamy S., Liu L.L., Liu M.Y. 17Beta-estradiol protects against acetaminophen-overdose-induced acute oxidative hepatic damage and increases the survival rate in mice. Steroids 2010, 76:118-124.
13. Chen J., Delannoy M., Odwin S., He P., Trush M.A., Yager J.D. Enhanced mitochondrial gene transcript, ATP, bcl-2 protein levels, and altered glutathione distribution in ethinyl estradiol-treated cultured female rat hepatocytes. Toxicol. Sci. 2003, 75:271-278.
14. Christensen B., Kazanecki C.C., Petersen T.E., Rittling S.R., Denhardt D.T., Sorensen E.S. Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties. J. Biol. Chem. 2007, 282:19463-19472.
15. Craig A.M., Denhardt D.T. The murine gene encoding secreted phosphoprotein 1 (osteopontin): promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene 1991, 100:163-171.
16. Dai G., He L., Chou N., Wan Y.J. Acetaminophen metabolism does not contribute to gender difference in its hepatotoxicity in mouse. Toxicol. Sci. 2006, 92:33-41.
17. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 2001, 107:1055-1061.
18. Diao H., Kon S., Iwabuchi K., Kimura C., Morimoto J., Ito D., Segawa T., Maeda M., Hamuro J., Nakayama T., Taniguchi M., Yagita H., Van Kaer L., Onoe K., Denhardt D., Rittling S., Uede T. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 2004, 21:539-550.
19. El-Tanani M.K., Campbell F.C., Kurisetty V., Jin D., McCann M., Rudland P.S. The regulation and role of osteopontin in malignant transformation and cancer. Cytokine Growth Factor Rev. 2006, 17:463-474.
20. Fan K., Dai J., Wang H., Wei H., Cao Z., Hou S., Qian W., Wang H., Li B., Zhao J., Xu H., Yang C., Guo Y. Treatment of collagen-induced arthritis with an anti-osteopontin monoclonal antibody through promotion of apoptosis of both murine and human activated T cells. Arthritis Rheum. 2008, 58:2041-2052.
21. Gao C., Guo H., Wei J., Kuo P.C. Osteopontin inhibits expression of cytochrome c oxidase in RAW 264.7 murine macrophages. Biochem. Biophys. Res. Commun. 2003, 309:120-125.
22. Geissinger E., Weisser C., Fischer P., Schartl M., Wellbrock C. Autocrine stimulation by osteopontin contributes to antiapoptotic signalling of melanocytes in dermal collagen. Cancer Res. 2002, 62:4820-4828.
23. Gonzalez F.J. Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat. Res. 2005, 569:101-110.
24. Ishijima M., Tsuji K., Rittling S.R., Yamashita T., Kurosawa H., Denhardt D.T., Nifuji A., Ezura Y., Noda M. Osteopontin is required for mechanical stress-dependent signals to bone marrow cells. J. Endocrinol. 2007, 193:235-243.
25. Janani P., Sivakumari K., Parthasarathy C. Hepatoprotective activity of bacoside A against N-nitrosodiethylamine-induced liver toxicity in adult rats. Cell Biol. Toxicol. 2009, 25:425-434.
26. Kaplowitz N. Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis. 2002, 22:137-144.
27. Katan M.B. Nitrate in foods: harmful or healthy?. Am. J. Clin. Nutr. 2009, 90:11-12.
28. Kazanecki C.C., Uzwiak D.J., Denhardt D.T. Control of osteopontin signaling and function by post-translational phosphorylation and protein folding. J. Cell. Biochem. 2007, 102:912-924.
29. Kemp C.J., Leary C.N., Drinkwater N.R. Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:7505-7509.
30. Kim H.J., Lee H.J., Jun J.I., Oh Y., Choi S.G., Kim H., Chung C.W., Kim I.K., Park I.S., Chae H.J., Kim H.R., Jung Y.K. Intracellular cleavage of osteopontin by caspase-8 modulates hypoxia/reoxygenation cell death through p53. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15326-15331.
31. Lamsa V., Levonen A.L., Leinonen H., Yla-Herttuala S., Yamamoto M., Hakkola J. Cytochrome P450 2A5 constitutive expression and induction by heavy metals is dependent on redox-sensitive transcription factor Nrf2 in liver. Chem. Res. Toxicol. 2010, 23:977-985.
32. Lee J.L., Wang M.J., Sudhir P.R., Chen G.D., Chi C.W., Chen J.Y. Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells. Cancer Res. 2007, 67:2089-2097.
33. -ΔΔCT Method. Methods 2001, 25:402-408.
34. Lorena D., Darby I.A., Gadeau A.P., Leen L.L., Rittling S., Porto L.C., Rosenbaum J., Desmouliere A. Osteopontin expression in normal and fibrotic liver. altered liver healing in osteopontin-deficient mice. J. Hepatol. 2006, 44:383-390.
35. Malato Y., Sander L.E., Liedtke C., Al-Masaoudi M., Tacke F., Trautwein C., Beraza N. Hepatocyte-specific inhibitor-of-kappaB-kinase deletion triggers the innate immune response and promotes earlier cell proliferation during liver regeneration. Hepatology (Baltimore, MD) 2008, 47:2036-2050.
36. Malorni W., Campesi I., Straface E., Vella S., Franconi F. Redox features of the cell: a gender perspective. Antioxid. Redox Signaling 2007, 9:1779-1801.
37. Martindale J.L., Holbrook N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol. 2002, 192:1-15.
38. Maselli A., Matarrese P., Straface E., Canu S., Franconi F., Malorni W. Cell sex: a new look at cell fate studies. FASEB J. 2009, 23:978-984.
39. Matsui A., Mochida S., Ohno A., Nagoshi S., Hirose T., Fujiwara K. Plasma osteopontin levels in patients with fulminant hepatitis. Hepatol. Res. 2004, 29:202-206.
40. Nakae D., Kobayashi Y., Akai H., Andoh N., Satoh H., Ohashi K., Tsutsumi M., Konishi Y. Involvement of 8-hydroxyguanine formation in the initiation of rat liver carcinogenesis by low dose levels of N-nitrosodiethylamine. Cancer Res. 1997, 57:1281-1287.
41. Nakatani T., Roy G., Fujimoto N., Asahara T., Ito A. Sex hormone dependency of diethylnitrosamine-induced liver tumors in mice and chemoprevention by leuprorelin. Jpn. J. Cancer Res. 2001, 92:249-256.
42. Naugler W.E., Sakurai T., Kim S., Maeda S., Kim K., Elsharkawy A.M., Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science (New York, NY) 2007, 317:121-124.
43. Norman A.W., Mizwicki M.T., Norman D.P. Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat. Rev. Drug Discovery 2004, 3:27-41.
44. Ramaiah S.K., Rittling S. Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol. Sci. 2008, 103:4-13.
45. Rangaswami H., Bulbule A., Kundu G.C. Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol. 2006, 16:79-87.
46. Sakurai T., He G., Matsuzawa A., Yu G.Y., Maeda S., Hardiman G., Karin M. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008, 14:156-165.
47. Schwartz A.G. Protective effect of benzoflavone and estrogen against 7,12-dimethylbenz(a)anthracene- and aflatoxin-induced cytotoxicity in cultured liver cells. Cancer Res. 1974, 34:10-15.
48. Scott J.A., Weir M.L., Wilson S.M., Xuan J.W., Chambers A.F., McCormack D.G. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am. J. Physiol. 1998, 275:H2258-H2265.
49. Shiota G., Maeta Y., Mukoyama T., Yanagidani A., Udagawa A., Oyama K., Yashima K., Kishimoto Y., Nakai Y., Miura T., Ito H., Murawaki Y., Kawasaki H. Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2'-deoxyguanosine formation. Hepatology 2002, 35:1125-1133.
50. Singh K., Sirokman G., Communal C., Robinson K.G., Conrad C.H., Brooks W.W., Bing O.H., Colucci W.S. Myocardial osteopontin expression coincides with the development of heart failure. Hypertension 1999, 33:663-670.
51. Tejura S., Rodgers G.R., Dunion M.H., Parsons M.A., Underwood J.C., Ingleton P.M. Sex-steroid receptors in the diethylnitrosamine model of hepatocarcinogenesis: modifications by gonadal ablation and steroid replacement therapy. J. Mol. Endocrinol. 1989, 3:229-237.
52. Vanacker J.M., Pettersson K., Gustafsson J.A., Laudet V. Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta. EMBO J. 1999, 18:4270-4279.
53. Veal E.A., Day A.M., Morgan B.A. Hydrogen peroxide sensing and signaling. Mol. Cell 2007, 26:1-14.
54. Verna L., Whysner J., Williams G.M. N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. Pharmacol. Ther. 1996, 71:57-81.
55. Wang K.X., Denhardt D.T. Osteopontin: role in immune regulation and stress responses. Cytokine Growth Factor Rev. 2008, 19:333-345.
56. Welch K.D., Reilly T.P., Bourdi M., Hays T., Pise-Masison C.A., Radonovich M.F., Brady J.N., Dix D.J., Pohl L.R. Genomic identification of potential risk factors during acetaminophen-induced liver disease in susceptible and resistant strains of mice. Chem. Res. Toxicol. 2006, 19:223-233.
57. Yamada K., Yamamiya I., Utsumi H. In vivo detection of free radicals induced by diethylnitrosamine in rat liver tissue. Free Radical Biol. Med. 2006, 40:2040-2046.
58. Zhao J., Dong L., Lu B., Wu G., Xu D., Chen J., Li K., Tong X., Dai J., Yao S., Wu M., Guo Y. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135:956-968.
59. Zohar R., Zhu B., Liu P., Sodek J., McCulloch C.A. Increased cell death in osteopontin-deficient cardiac fibroblasts occurs by a caspase-3-independent pathway. Am. J. Physiol. Heart Circ. Physiol. 2004, 287:H1730-H1739.